FMC reported +6% higher FY revenues (to USD16,738m) and the gross profit margin rose 30bp to 31.9%. EBITDA saw a +3% improvement (to USD3,044m), but the respective margin dropped from 18.7% to 18.2%. Net income attributable to shareholders came in at USD1,029m. Operating CF improved +5% to USD1,960m, driven by higher net income and lower NWC outflow. Investing CF dropped from USD-2,690m to USD-1,001m primarily due to lower acquisition costs (USD—317m after USD1,779m). FCF swung from USD

24 Feb 2016
FY guidance barely met excluding one-offs

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY guidance barely met excluding one-offs
Fresenius Medical Care AG (FME:WBO) | 0 0 0.7% | Mkt Cap: 26,769m
- Published:
24 Feb 2016 -
Author:
Martin Schnee -
Pages:
2 -
FMC reported +6% higher FY revenues (to USD16,738m) and the gross profit margin rose 30bp to 31.9%. EBITDA saw a +3% improvement (to USD3,044m), but the respective margin dropped from 18.7% to 18.2%. Net income attributable to shareholders came in at USD1,029m. Operating CF improved +5% to USD1,960m, driven by higher net income and lower NWC outflow. Investing CF dropped from USD-2,690m to USD-1,001m primarily due to lower acquisition costs (USD—317m after USD1,779m). FCF swung from USD